Journey Medical Analyst Ratings
Journey Medical Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/12/2023 | 167.85% | B. Riley Securities | $3 → $6 | Maintains | Buy |
| 05/23/2023 | 33.92% | B. Riley Securities | $6 → $3 | Maintains | Buy |
| 03/30/2023 | 167.85% | B. Riley Securities | → $6 | Reiterates | → Buy |
| 02/25/2022 | 301.77% | Cantor Fitzgerald | → $9 | Initiates Coverage On | → Overweight |
| 12/16/2021 | 569.61% | Roth Capital | → $15 | Initiates Coverage On | → Buy |
| 12/07/2021 | 524.97% | B. Riley Securities | → $14 | Initiates Coverage On | → Buy |
| 02/03/2020 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 01/23/2020 | 737.02% | HC Wainwright & Co. | → $18.75 | Downgrades | Buy → Neutral |
| 06/06/2019 | 524.97% | Mizuho | $17 → $14 | Upgrades | Neutral → Buy |
| 06/06/2019 | 524.97% | Mizuho | $17 → $14 | Upgrades | Neutral → Buy |
| 02/14/2019 | 480.33% | HC Wainwright & Co. | → $13 | Initiates Coverage On | → Buy |
| 01/17/2019 | — | Raymond James | Upgrades | Underperform → Market Perform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 07/12/2023 | 167.85% | B.莱利证券 | $3→$6 | 维护 | 买 |
| 2023年05月23日 | 33.92% | B.莱利证券 | $6→$3 | 维护 | 买 |
| 03/30/2023 | 167.85% | B.莱利证券 | →$6 | 重申 | →购买 |
| 02/25/2022 | 301.77% | 康托·菲茨杰拉德 | →$9 | 开始承保 | →超重 |
| 12/16/2021 | 569.61% | 罗斯资本 | →$15 | 开始承保 | →购买 |
| 12/07/2021 | 524.97% | B.莱利证券 | →$14 | 开始承保 | →购买 |
| 02/03/2020 | - | 古根海姆 | 评级下调 | 购买→中性 | |
| 1/23/2020 | 737.02% | HC Wainwright公司 | →$18.75 | 评级下调 | 购买→中性 |
| 2019年06月06日 | 524.97% | 瑞穗 | $17→$14 | 升级 | 中性→购买 |
| 2019年06月06日 | 524.97% | 瑞穗 | $17→$14 | 升级 | 中性→购买 |
| 2019年02月14日 | 480.33% | HC Wainwright公司 | →$13 | 开始承保 | →购买 |
| 2019年01月17日 | - | 雷蒙德·詹姆斯 | 升级 | 表现逊于→市场表现 |
What is the target price for Journey Medical (DERM)?
旅程医疗(DERM)的目标价格是多少？
The latest price target for Journey Medical (NASDAQ: DERM) was reported by B. Riley Securities on July 12, 2023. The analyst firm set a price target for $6.00 expecting DERM to rise to within 12 months (a possible 167.85% upside). 3 analyst firms have reported ratings in the last year.
旅行医疗(纳斯达克：DEM)的最新目标价是由B.莱利证券于2023年7月12日报道的。这家分析公司将目标价定为6美元，预计美元兑美元汇率将在12个月内升至(可能上涨167.85)。3家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Journey Medical (DERM)?
旅程医疗(DERM)的最新分析师评级是什么？
The latest analyst rating for Journey Medical (NASDAQ: DERM) was provided by B. Riley Securities, and Journey Medical maintained their buy rating.
旅行医疗(纳斯达克代码：DEM)的最新分析师评级由B.莱利证券提供，旅行医疗维持买入评级。
When is the next analyst rating going to be posted or updated for Journey Medical (DERM)?
旅程医疗(DERM)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Journey Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Journey Medical was filed on July 12, 2023 so you should expect the next rating to be made available sometime around July 12, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Journey Medical的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。旅程医疗的上一次评级是在2023年7月12日提交的，所以你应该预计下一次评级将在2024年7月12日左右的某个时候提供。
Is the Analyst Rating Journey Medical (DERM) correct?
分析师对Journey Medical(DERM)的评级正确吗？
While ratings are subjective and will change, the latest Journey Medical (DERM) rating was a maintained with a price target of $3.00 to $6.00. The current price Journey Medical (DERM) is trading at is $2.24, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的旅程医疗(DERM)评级保持不变，目标价在3.00美元至6.00美元之间。目前Journey Medical(DERM)的交易价格为2.24美元，超出了分析师的预测范围。
译文内容由第三方软件翻译。